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Abstract
Background: Anal incontinence is a disabling condition that adversely affects the quality of life of a large number
of patients, mainly with anal sphincter lesions. In a previous experimental work, in-vitro expanded bone marrow
(BM)-derived mesenchymal stem cells (MSC) were demonstrated to enhance sphincter healing after injury and
primary repair in a rat preclinical model. In the present article we investigated whether unexpanded BM
mononuclear cells (MNC) may also be effective.
Methods: Thirty-two rats, divided into groups, underwent sphincterotomy and repair (SR) with primary suture of
anal sphincters plus intrasphincteric injection of saline (CTR), or of in-vitro expanded MSC, or of minimally
manipulated MNC; moreover, the fourth group underwent sham operation. At day 30, histologic, morphometric,
in-vitro contractility, and functional analysis were performed.
Results: Treatment with both MSC and MNC improved muscle regeneration and increased contractile function of
anal sphincters after SR compared with CTR (p < 0.05). No significant difference was observed between the two BM
stem cell types used. GFP-positive cells (MSC and MNC) remained in the proximity of the lesion site up to 30 days
post injection.
Conclusions: In the present study we demonstrated in a preclinical model that minimally manipulated BM-MNC
were as effective as in-vitro expanded MSC for the recovery of anal sphincter injury followed by primary sphincter
repair. These results may serve as a basis for improving clinical applications of stem cell therapy in human anal
incontinence treatment.
Keywords: Anal incontinence, Anal sphincter injury, Bone marrow mononuclear cells, Bone marrow mesenchymal
stem cells, Anal sphincter repair
Background
Anal incontinence is a disabling condition that adversely
affects the quality of life of a considerable number of pa-
tients (2–15 % of the general population) [1, 2]. Injury of
the anal sphincters (mainly post surgical or post deliv-
ery) is the most common cause of incontinence, and sur-
gical repair is actually the treatment of choice. Clinical
studies reported a relatively good success rate of surgical
repair in patients with sphincter lesions but the initial
results worsened in time with only 30 % of patients dem-
onstrating full continence 5 years after surgery [3–5].
Other approaches such as the use of injectable bulking
agents to augment anal sphincter function have been used
recently in several observational studies [6] but generally
resulted in poor outcomes [3, 7].
Recently, the use of adult stem cells (ASC) in regen-
erative medicine protocols has become a promising
therapeutic approach for organ or tissue repair when the
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conventional therapies are ineffective [8]. Bone marrow
(BM) is currently the most used source of ASC for clin-
ical use, containing hematopoietic stem cells (HSC),
endothelial precursor cells (EPC), and mesenchymal
stem cells (MSC). Clinical studies predominantly use
mononuclear cells (MNC) isolated from BM aspirates by
density gradient centrifugation. Autologous local im-
plantation of BM-MNC represents a novel strategy for
the achievement of therapeutic angiogenesis and neovas-
cularization in patients affected by peripheral arterial
diseases [9–11]. Furthermore, BM-MNC (CD34+ and
CD133+) are the most common BM cell types used in
clinical trials for patients with acute myocardial infarc-
tion and ischemic cardiomyopathy over the last decade
[12]. Another approach in regenerative medicine as-
sumes ex-vivo expansion of mesenchymal progenitors to
reach adequate numbers for surgical application [13, 14].
MSC isolated from BM can be transferred and/or ex-
panded on appropriate biocompatible support before
clinical use, mainly in the orthopedic field [15].
BM-MSC or muscle-derived stem cells (MDSC) have
been used in preclinical and clinical studies demonstrat-
ing the efficacy of this treatment in repairing anal
sphincter lesions and in improving symptoms of anal in-
continence [16–22]. In our previous works [16, 23] we
successfully reported the local injection of syngeneic
MSC as a potential treatment of anal as well as esopha-
geal injury in preclinical models. In both cases, injected
MSC led to the formation of new myofibers, and im-
proved the contractility of sphincters after injury.
However, employment of MSC and particularly in-
vitro expansion of stem cells for clinical use is strongly
hindered by the necessity to lean on a good manufactur-
ing practices (GMP) facility, following strict standard
operating procedures established by the European
Medicines Evaluation Agency (EMEA), and hence re-
quires work in accredited structures whose mainten-
ance is very demanding and expensive. On the
contrary, MNC represent a source of stem cells which
can be easily isolated from BM with minimal manipu-
lation within an automated closed system contempor-
arily to the surgical operation.
We therefore designed the present study to assess
whether minimally manipulated MNC were as effective
as in-vitro expanded MSC in a preclinical experimental
model of sphincterotomy and repair (SR) with primary
suture of anal sphincters, with the aim of a possible clin-




The study was approved by the local Ethics Committee
and by the Italian Ministry of Health according to Italian
Law (D.lgs 116/92, article 7), and all procedures were
carried out according to European legislation following
the guidelines for care and use of laboratory animals.
Male inbred Lewis rats (weight range 250–300 g) from
Charles River Laboratories (Lecco, Italy) and male green
fluorescent protein (GFP) transgenic Lewis rats from
RRRC (Columbia, MO, USA) were used. All animals
were housed in single cages with a natural night and day
cycle, free access to water, and a commercial pellet diet
(Harlan, Udine, Italy) ad libitum. Preoperative and post-
operative clinical evaluation was carried out and the
feeding and defecation behavior was observed daily to
verify fecal continence and detect possible complica-
tions. Rats were euthanized using an anesthetic overdose
followed by exsanguination 30 days after treatment.
BM-MNC and BM-MSC isolation and characterization
Rat BM was isolated from male GFP transgenic Lewis
rats (RRRC), as described previously [23].
MNC were obtained by density gradient (Hystopaque)
stratification of whole BM and centrifugation at 600 × g
for 30 min. The ring containing the MNC fraction was
harvested, resuspended in saline containing 1 % fetal bo-
vine serum (FBS; HyClone, South Logan, UT, USA), and
washed three times (300 × g for 7 min).
MSC were isolated from whole BM by plastic adher-
ence and in-vitro expanded as described previously [23].
The differentiation ability of MSC toward osteogenic
and adipogenic lineages was evaluated as described pre-
viously [23].
MSC were characterized and analyzed for the expres-
sion of particular cell surface molecules by flow cy-
tometry: CD45-CyChrome™, CD11b-FITC (in order to
quantify hematopoietic-monocytic contamination), CD90-
PE, CD106-PE, CD73-PE, and CD44-PE (BD Pharmingen,
San Diego, CA, USA). 7-AAD was added to exclude dead
cells from the analysis. Green fluorescence intensity was
assessed by flow cytometric analysis on freshly isolated
BM-MSC as well as on BM-MSC at different passages in
culture. Flow cytometric acquisition for both BM-MNC
and BM-MSC was performed by collecting 104 events on
a FACScalibur (Becton Dickinson, San Jose, CA, USA) in-
strument, and data were analyzed on DOT-PLOT bi-
parametric diagrams using CELL QUEST PRO software
(Becton Dickinson).
Experimental model
Thirty-two male Lewis rats (Charles River Laboratories)
were used. Animals were divided into four subgroups of
eight animals each. The first group, as control (CTR),
underwent SR of the anal sphincter plus saline injec-
tions. A second group underwent SR of the anal sphinc-
ter followed by intrasphincteric injections of syngeneic
in-vitro expanded BM-derived GFP-MSC (MSC group).
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A third group underwent SR of the anal sphincter
followed by intrasphincteric injections of syngeneic min-
imally manipulated BM-derived GFP-MNC (MNC group).
The fourth group underwent sham operation without
sphincter injury plus intrasphincteric saline solution injec-
tions (SHAM group).
Sphincterotomy was carried out under an operating
microscope (Carl Zeiss OMPI CS XY) by an open, left lat-
eral, full thickness sphincterotomy of both anal sphincters
as described previously [16]. Using a Hamilton syringe
and under a microscopic guide, a single injection of 10 μl
of MSC (0.75 × 106 cells/10 μl; total MSC injected/animal:
3 × 106), 10 μl of MNC (mean MNC injected/animal:
7.38 × 106 ± 1.59), or 10 μl saline solution was subse-
quently made in each cut end of both sphincters (four in-
jections of 10 μl in each animal). On sham-operated
animals, two injections of saline solution (10 μl) were per-
formed at the 3-o’clock position of each isolated sphincter.
The skin wound was then closed with absorbable sutures.
Animals were sacrificed at 30 days after the treatment.
Half of the animals of each group were examined for
histological studies (n = 4) and half for contractility re-
sponses (n = 4).
Histologic, immunohistochemical, morphometric study
A ring specimen including the anal canal and the ter-
minal rectum was removed en bloc, snap frozen imme-
diately after collection in isopentane precooled in liquid
nitrogen, and preserved at –80 °C. Serial cryostat sec-
tions, 10 μm thick, were fixed overnight at –20 °C in for-
maldehyde vapors [24] and stored at –80 °C until use
[23]. Some of these sections were stained with 0.1 %
toluidine blue and used to quantify the regeneration of
the sphincters. Because sections stained with toluidine
blue provide a less detailed visualization and anatomic
resolution of the anal sphincter complex than those em-
bedded in methacrylate, the whole tissue at the site of
SR was examined without separate analysis of each
sphincter. A mean of eight microscopic fields were
manually searched at the site of repair at 4× magnifica-
tion and the muscle area fraction (MAF) was evaluated
with the “Area” function of the Nikon NIS-Elements
software version 2.30 and calculated as differences be-
tween the area of muscle elements and the total area ex-
amined. Data were expressed as a percentage of the
mean value of the control’s total area. The analysis was
performed by two independent operators in a blinded
fashion.
Other cryostat sections were used for double immuno-
fluorescence staining for alpha smooth muscle actin
(α-SMA) and GFP. Sections were first incubated overnight
at 4 °C with a mouse monoclonal antibody to α-SMA
(Sigma-Aldrich; 1:400 in phosphate-buffered saline (PBS)
with 1 % bovine serum albumin (BSA)), and the reaction
was revealed with Alexa Fluor 594 (Molecular Probes-
Invitrogen, Milan, Italy). The second immunostaining was
performed for 2 h at room temperature with a rabbit poly-
clonal antibody to GFP (Molecular Probes-Invitrogen)
diluted 1:200 in PBS with 1 % BSA. The reaction was re-
vealed with a FITC-conjugated secondary antibody. As
negative controls sections of the sham-operated group or
sections of the other two groups with omission of the pri-
mary antibody were used. Sections were mounted with
DABCO mounting medium (Sigma-Aldrich). All samples
were observed under a Nikon Eclipse E600 microscope
and images were acquired with Nikon Nis-Elements AR
2.30 software.
Contractility study
For sphincter and strip preparations, a ring segment
comprising 2 mm of the terminal rectum including the
anal orifice was removed and cleaned from extraneous
tissue by sharp dissection. The anorectal region was then
opened at the opposite side of the resection site and
pinned flat with the mucosal side up to form a strip of
circularly arranged tissue. After the removal of the mu-
cosa, the internal smooth muscle sphincter was identi-
fied and finely dissected following the direction of the
muscle bundles with the help of an optic microscope
obtaining one strip from each sphincter. Strips were tied
to each end with fine silk ligatures, mounted in organ
baths (0.2 ml) between two platinum ring electrodes,
and continuously superfused with oxygenated (95 % O2,
5 % CO2) Krebs solution (pH 7.2; 37 °C). Each muscle
strip was stretched to 1 g tension and given at least 1 h
to equilibrate. The functionality of the strips was tested
by stimulating each strip both electrically (frequency
from 1 to 15 Hz, 50 V voltage, 0.01 ms duration, 5-
second train pulses) and with carbachol (CCH), a cholin-
ergic agonist. Frequency-response curves have also been
performed in the presence of tetrotodoxin (data not
shown) to confirm nerve stimulation [16].
Statistical analysis
Statistical analysis of the data was performed by Student’s
t test for unpaired samples, or by one-way ANOVA
followed by Dunnett’s post test for multiple comparisons.
p < 0.05 was considered significant.
Results
BM-MSC and BM-MNC characteristics
GFP-MSC were isolated from GFP transgenic Lewis rats,
expanded, and characterized as described previously
[23]. GFP-MSC were able to differentiate toward osteo-
genic as well as adipogenic lineage upon specific stimu-
lation. Flow cytometric analysis showed GFP expression
over 94 % at every passage along with the presence of
mesenchymal markers (CD90, CD106, CD73, CD44).
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There was no contamination of hematopoietic cells as
flow cytometry was negative for markers of hematopoietic
lineage CD11c and CD45.
GFP-MNC were isolated from BM by density gradient
separation. Flow cytometric analysis showed GFP ex-
pression over 95 %. Viability of infused cells (MSC and
MNC), measured by 7-AAD before injection, was always
over 90 %.
Anal sphincter functionality
The contractile ability of the internal anal sphincter was
determined by applying both exogenous CCH, a choliner-
gic agonist which acts on muscarinic receptors, and elec-
trical field stimulation (EFS) at selected parameters to
obtain a nerve-mediated response, as reported in Methods.
Smooth muscle anal sphincter strips stimulation with
10–5 M CCH gave rise to a submaximal contractile re-
sponse, expressed as milligrams of tension developed per
milligram of wet tissue. This contractile response was
significantly (p < 0.05) lower at day 30 after SR in the un-
treated animals (CTR) compared both with sham-
operated animals and with animals receiving either MNC
or MSC injection (Fig. 1).
Similar results were obtained when the smooth muscle
was electrically stimulated (nerve stimulation). The EFS
parameters used to stimulate smooth muscle strips de-
veloped a biphasic response: a relaxation response which
predominated at low stimulation frequencies, and a con-
tractile response becoming more relevant at higher fre-
quencies. Both relaxation and contraction were blocked
by 3 μM tetrotodoxin, thus confirming that the response
was nerve mediated (data not reported). SR resulted in a
significant loss of both relaxing (Fig. 2a) and contractile
(Fig. 2b) responses to EFS. Strips obtained from MNC-
treated and MSC-treated animals instead showed higher
values of both relaxation and contraction responses to
EFS at almost all frequencies of stimulation compared
with CTR animals. Moreover, these values were not sig-
nificantly different from those of sham-operated rats.
Sphincter smooth muscle contractile ability of MNC-
treated animals upon electrical as well as chemical
stimulation was thus comparable with that of the MSC-
treated group and seems to recover functionality almost
completely.
Histologic, immunohistochemical and morphometric
analysis
In the control group (CTR), the area of injury was easily
detected at day 30 post operation (Fig. 3a, b) as a gap
between the ends of the interrupted muscle layer filled
with scar tissue, inflammatory cells, and mast cells. In
contrast, in rats treated with BM-derived stem cells
(MSC or MNC) the injured area appeared almost com-
pletely repaired: the lesion area could be recognized by
the presence of residual suture material surrounded by
an inflammatory reaction (Fig. 3c–f). In the sham-operated
group that received intrasphincteric saline solution injec-
tion but no sphincter lesion, the muscular layer appeared
intact and no inflammatory infiltrate could be detected
(Fig. 3g, h).
Results of morphometric analysis (Fig. 4) showed that
the MAF was increased significantly in rats treated with
BM-MSC or BM-MNC compared with controls (59.1 ±
5.8 and 62.6 ± 7.7 % respectively vs 26.4 ± 6.6 %, p < 0.01).
No significant differences between expanded (MSC) and
minimally manipulated (MNC) stem cells were observed
(p = n.s.). MSC and MNC MAF values were, however,
significantly lower than those of sham-operated animals
(92.5 ± 2.7 %, p < 0.05).
We next sought to clarify what happened to GFP-
positive cells in the animals that underwent SR. Double
labeling for GFP and α-SMA allowed exact localization
of GFP-positive MSC or MNC cells in the intestinal
wall (Fig. 5). At day 30 after SR and BM-derived stem
cell injection, the lesion in most cases was almost
completely repaired and clusters of GFP-positive cells
could be detected at a distance from the repaired in-
jury site, in the proximity of the intestinal lumen or
around blood vessels (Fig. 5a, b). GFP-positive cells
could instead be detected at the site of injury in those
cases in which part of the lesion area had remained
unrepaired (Fig. 5c, d), as well as in the proximity of
residual suture material (Fig. 5e, f ). No colocalization
of GFP and smooth muscle cell marker α-SMA has
ever been observed.
Fig. 1 CCH (10–5 M) induced contractile responses of rat internal
anal sphincter strips. Results are expressed as milligrams of tension
developed per milligram of wet tissue (mean ± SEM for four rats).
*p < 0.05 vs SHAM, MSC, and MNC groups. CTR SR plus physiological
injection, MNC SR plus mononuclear cells injection, MSC SR plus
mesenchymal stem cells injection, SHAM sham operation
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Safety
No adverse reactions were observed during MNC as well
as MSC local injection.
Discussion
Repair of anal sphincter injuries is still a surgical chal-
lenge because many patients do not recover perfect con-
tinence after treatment. The reparative process needs to
be further investigated and the therapeutic strategy
improved.
Several strategies including in-vitro expanded stem
cells (muscular progenitors, adipose-derived MSC, BM-
derived MSC) alone or in bioengineered constructs have
been proposed and used in preclinical studies [16, 25–28]
and small clinical studies [29–31]. Results are promising
but limited to small numbers of patients. In addition,
European regulations impose the use of GMP cell factories
for in-vitro cell expansion, limiting the use of this
therapeutic strategy; therefore the use of minimally manip-
ulated cells could greatly improve stem cell-associated
surgery.
In the present study we demonstrated, in a preclinical
model, that minimally manipulated BM stem cells
(MNC) were as effective as in-vitro expanded BM-MSC
for the repair of anal sphincters after injury. MNC, ob-
tained after a simple gradient-based separation of whole
BM, were effective in lesion repair as well as for con-
tractile ability recovery. In particular, MNC locally
injected into the cut ends of anal sphincters after surgi-
cal repair led to the formation of new muscular tissue
and, consequently, improved the contractility of injured
anal sphincters as well as in-vitro expanded MSC. At 1
month, injection of MNC at the site of SR resulted in in-
creased sphincter masses and improved smooth muscle
responses of strips to chemical and electrical stimula-
tions compared with control animals. This improved
Fig. 2 EFS (1–15 Hz frequency, 50 V, 0.01 ms duration and 5-second trains) induced relaxation (a) and contraction (b) of rat smooth muscle anal
sphincter strips. Results are expressed as grams per milligram of wet tissue (mean ± SEM for four rats). *Significantly different from all other groups
(MNC, MSC, SHAM). CTR SR plus physiological injection, MNC SR plus mononuclear cells injection, MSC SR plus mesenchymal stem cells injection,
SHAM sham operation
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functionality of the smooth muscle sphincter is compar-
able with that observed after MSC treatment, further
supporting results obtained and reported in a previous
paper by our group [16].
Although the efficacy of in-vitro expanded progenitor
cells, mainly muscle progenitor cells or adipose tissue-
derived MSC, to improve contractile function of
repaired anal sphincters has been demonstrated in sev-
eral preclinical studies [18–20, 32], to our knowledge
this is the first study investigating the potential of min-
imally manipulated BM cells for the treatment of anal
sphincter lesions. Only one group compared the use of
minimally manipulated adipose tissue-derived cells with
in-vitro expanded adipose tissue MSCs [31] for the treat-
ment of Crohn’s anal fistula, demonstrating a limited ef-
ficacy of unexpanded stromal vascular fraction (SVF)
local injection in this clinical setting. However limited
numbers of patients have been evaluated and differences
Fig. 3 Area of sphincterotomy and repair (SR) at 30 days after operation. Cryostat sections at low magnification (left column) and same field at
higher magnification (right column). Toluidine blue staining. CTR (a, b), MSC (c, d), MNC (e, f), and sham operated (g, h) animals. At day 30 the
lesion is still visible in CTR animals (a, b) as a large gap in the muscular layer (M) filled with dense connective tissue and mast cells. It is instead
almost completely repaired and recognizable as a limited gap in the muscle layer in the animals that received intralesion injection of stem cells
either in-vitro expanded (c) or minimally manipulated (e). At higher magnification (d, f), numerous small clusters of smooth muscle cells are
irregularly interspersed in the fibrous connective tissue. In sham operated animals the muscular layer appeared intact (g, h). Magnification: a, c, e,
g × 2; b, d, f, h same field × 4
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with our results could be attributed to the different clin-
ical setting (anal fistula vs anal sphincter injury) as well
as to different cell source (i.e., adipose tissue and BM)
used.
Another interesting result of our study is that BM
stem cell injection (MNC as well as MSC) did not result
in differentiation into myofibers, as no colocalization of
GFP and α-SMA has ever been observed. At day 30 post
SR, stem cells were still present and localized in small
clusters near injured areas where the lesion was not
completely repaired or at distant sites in the case of al-
most intact tissue, further supporting data we previously
obtained in a rat model of lower esophageal sphincter
injury [23]. In that model we showed that injection at
the site of myotomy of syngeneic MSC resulted in
muscle regeneration and recovery of muscle contractil-
ity, although this was not associated with MSC differen-
tiation toward muscle tissue. GFP-positive MSC were
localized as compact clusters in the proximity of the
damaged area or at the periphery of the sphincter and
no colocalization with smooth or striated muscle
Fig. 4 MAF in controls (CTR), in sham-operated animals (SHAM), and
after local injection of in-vitro expanded (MSC) and minimally
manipulated (MNC) stem cells. Data are expressed as % of the mean
value of the control injured area (mean of eight microscopic
fields for each anal sphincter). °°p < 0.01 vs both MSC and MNC;
*p < 0.05, ***p < 0.001 vs SHAM. CTR SR plus physiological injection,
MNC SR plus mononuclear cells injection, MSC SR plus mesenchymal
stem cells injection, SHAM sham operation
Fig. 5 Destiny of GFP-positive cells. Cryostat serial sections. Toluidine blue staining (left column) and merged images of double labeling with α-SMA
and GFP (right column) of MSC-treated (a, b) and MNC-treated (c–f) rats. (a, b) The lesion is almost repaired in MSC-treated rats. Smooth muscle cells in
the muscular layer (M) and in the muscularis mucosae (mm) are α-SMA positive (red). Clusters of GFP-positive cells (green) are visible under the
epithelium. (c, d) A cluster of GFP-positive cells is still present inside the gap of a small not yet repaired area in a MNC-treated rat. (e, f) GFP-positive
cells are present around a suture thread (arrowheads, yellow due to autofluorescence) in a MNC-treated rat. Original magnification × 10
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markers has been observed at the different time points
(7, 14 and 30 days post injection) analyzed, supporting
the role of paracrine effects in lesion repair [23]. It
should be taken into consideration that only preclinical
studies using myoblast cell therapy were able to demon-
strate a direct involvement (differentiation) of implanted
cells in the formation of new muscle fibers associated
with restoration of anal sphincter function [22, 32]. Un-
committed cells such as MSC were able to restore con-
tractile function, although this was not associated with
their myogenic differentiation [19] or their persistence
in the site of injury [18–20] but probably with a pattern
of cytokine secretion favoring local progenitor prolifera-
tion [20]. Indeed the paracrine mechanism of stromal
cells has been well demonstrated for improvement of
cardiac function [33] as well as for the restoration of ur-
ethral function in a urinary incontinence model [34].
Most importantly, in our preclinical model of anal
sphincter injury, in-vitro expanded MSC and minimally
manipulated BM-MNC seem to have comparable effects
in improving muscle regeneration during repair after SR.
Stem cells remained at the site of injury until inflamma-
tion/damage was present, showing the same efficacy in
supporting tissue regeneration and the restoration of
contractility.
These results have important implications for stem cell
clinical use because BM-MNC may be easily harvested
and processed in a closed automated system during sur-
gical repair (no time is required for cell expansion),
favoring stem cell regenerative potential in a simplified
and rapid GMP procedure.
Conclusions
BM stem cell injection into the anal sphincters could
represent a new therapeutic strategy for the treatment of
sphincter lesions, thereby improving anal incontinence.
This treatment could be employed alone by echo-guided
transcutaneous injections in focal areas of the sphincter
lesions or could be used together with surgical repair of
the anal sphincters, thus constituting a new approach
for the cure of several types of anal sphincter lesions
with the aim to reduce the risk of fecal incontinence.
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